Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease.
calculated body muscle mass
grip strength
liver disease
sarcopenia
sarcopenia index
skeletal muscle mass
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
13
09
2019
revised:
06
02
2020
accepted:
07
02
2020
pubmed:
16
2
2020
medline:
16
2
2020
entrez:
16
2
2020
Statut:
ppublish
Résumé
Sarcopenia is a harmful condition in patients with chronic liver disease. However, the evaluation of body muscle mass requires expensive instrumentation. The sarcopenia index (SI): (creatinine / cystatin C × 100) has been reported to correlate with muscle volume. A calculated body muscle mass (CBMM) using creatinine, cystatin C, and bodyweight also correlates with muscle mass. We evaluated the applicability of using SIs and CBMMs as screening methods for sarcopenia. Patients (n = 303) with liver damage were evaluated for creatinine, cystatin C, and grip strength (GS). All patients were evaluated using cross-sectional computed tomography images of the third lumbar vertebrae to determine their skeletal muscle (SM) mass. CBMMs and SIs were compared with SMs, GSs, and sarcopenia. Correlation coefficients (R) between SMI (SM / height CBMMs and SIs are simple and minimally invasive screening methods in which low levels are indicative of sarcopenia in patients with liver disease.
Types de publication
Journal Article
Langues
eng
Pagination
704-714Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
van Vugt JLA, Alferink LJM, Buettner S et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol 2018; 68: 707-714.
Golse N, Bucur PO, Ciacio O et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl 2017; 23: 143-154.
Yamashima M, Miyaaki H, Honda T et al. Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib. Mol Clin Oncol 2017; 7: 449-453.
Fujiwara N, Nakagawa H, Kudo Y et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131-140.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010; 39: 412-423.
Fielding RA, Vellas B, Evans WJ et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12(4): 249-256.
Chen LK, Liu LK, Woo J et al. Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014; 15: 95-101.
Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31.
Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 2016; 46: 951-963.
Nishikawa H, Enomoto H, Ishii A et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle 2017; 8: 915-925.
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14: 513-537.
Fife E, Kostka J, Kroc Ł et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr 2018; 18: 200.
Kashani KB, Frazee EN, Kukrálová L et al. Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Crit Care Med 2016; 45: 1-7.
Barreto EF, Poyant JO, Coville HH, Dierkhising RA, Kennedy CC, Gajic O, Nystrom EM, Takahashi N, Moynagh MR, Kashani KB. Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers. Clin Nutr 2018, 38, 1362, 1367.
Kashani K, Sarvottam K, Pereira NL, Barreto EF, Kennedy CC. The sarcopenia index: A novel measure of muscle mass in lung transplant candidates. Clin Transplant 2018; 32: e13182.
Osaka T, Hamaguchi M, Hashimoto Y et al. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract 2018; 139: 52-58.
Tamai Y, Iwasa M, Kawasaki Y et al. Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma. Hepatol Res 2019; 49: 153-163. https://doi.org/10.1111/hepr.13230.
Kim SW, Jung HW, Kim CH, Kim K, Chin HJ, Lee H. A new equation to estimate muscle mass from creatinine and cystatin C. PLoS ONE 2016; 11: e0148495.
Hiraoka A, Aibiki T, Okudaira T et al. Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation. J Gastroenterol 2015; 50: 1206-1213.
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade. J Clin Oncol 2015; 33: 550-558.
Kamath P, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007; 46: 32-36.
Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
Eckardt K-U, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. Am. J. Kidney Dis 2009; 53: 915-920.
Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology 2017; 65: 1044-1057.
Yoo J-J, Kim S, Kim Y et al. Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex. J Hepatol [Internet] 2019; 70: 847-854 Available from: https://browzine.com/articles/260605879.
Mindikoglu AL, Opekun AR, Mitch WE et al. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci 2018; 63: 665-675.
Moctezuma-Velázquez C, Low G, Mourtzakis M et al. Association between low testosterone levels and sarcopenia in cirrhosis: A cross-sectional study. Ann Hepatol 2018; 17: 615-623.
Patel SS, Molnar MZ, Tayek JA et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: Results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 2013; 4: 19-29.
Ida S, Kojima Y, Hamaoka S et al. Validity of Japanese version of SARC-F questionnaire in patients with chronic liver disease. J Gastroenterol Hepatol 2019; 34: 947-953.
Hiraoka A, Nagamatsu K, Izumoto H et al. SARC-F combined with simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatol Res [Internet] 2019. [cited 2019 Dec 26];hepr.13469. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31830344.